Essential medicines and health products

First EC/ACP/WHO Partnership on Pharmaceutical Policies


About the first partnership

Positive evaluation for the Partnership

An end of program evaluation completed in the fall of 2010 found an inextricable link between the Partnership’s activities and participant country progress towards several health-related MDGs, in particular because of the role that successful implementation of the world medicines strategy plays in health systems strengthening more broadly. The Partnership was especially praised for aligning to national priorities and plans and for its proactive approach, which adjusts ongoing activities as new needs arise. Another important value add of the Partnership was the successful expansion of WHO activities to support countries, both at the headquarters and at the regional and sub-regional levels.

Established in March 2004, the EC/ACP/WHO Partnership on Pharmaceutical Policies dedicated €25 million to the strategic and technical support of African, Caribbean and Pacific Island (ACP) countries in the development and implementation of essential medicines strategies. The ultimate aim of the programme is to save lives and improve population health in ACP countries - particularly within poor and disadvantaged communities - by improving the availability and affordability of essential medicines and ensuring acceptable standards on drug quality, safety and use. ACP countries receive technical and financial support to improve pharmaceutical sector performance through the following core activities:

  • Development, monitoring and evaluation of national medicines policies (NMPs).
  • Strengthening of the pharmaceutical system in all its components. This includes improvement of the regulation, financing, procurement and governance of pharmaceuticals; as well as the strengthening of human resources for health, which is among our priorities.
  • Promotion of best practices, through specific support to countries, sub-regional groups and regions.

Key Documents

Share